Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from CellSource Co., Ltd. ( (JP:4880) ).
CellSource Co., Ltd. reported a significant increase in contract processing orders for October 2025, with notable growth in the orthopedics and OB&GYN departments. The company achieved a 68% increase in hybrid orthopedics orders and a 28% rise in OB&GYN orders, reflecting the success of strategic measures implemented throughout the fiscal period.
The most recent analyst rating on (JP:4880) stock is a Hold with a Yen547.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the biotechnology industry, focusing on contract processing services for blood-derived products. The company is listed on the Tokyo Stock Exchange and emphasizes its services in orthopedics and OB&GYN sectors.
Average Trading Volume: 81,052
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen9.91B
Learn more about 4880 stock on TipRanks’ Stock Analysis page.